Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Spezial am Donnerstag: Rallye II. - Neuer Anstoß, News und was die Börsencommunity jetzt nicht verpassen will…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12GDU | ISIN: US23283X2062 | Ticker-Symbol: HQE1
Tradegate
27.03.24
21:52 Uhr
0,829 Euro
-0,047
-5,37 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
CYTOSORBENTS CORPORATION Chart 1 Jahr
5-Tage-Chart
CYTOSORBENTS CORPORATION 5-Tage-Chart
RealtimeGeldBriefZeit
0,8300,89028.03.
0,8500,90228.03.

Aktuelle News zur CYTOSORBENTS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.03.Cytosorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript3
15.03.Cytosorbents Corp reports results for the quarter ended in December - Earnings Summary4
14.03.Cytosorbents GAAP EPS of -$0.64 misses by $0.02, revenue of $31.09M misses by $6.4M6
14.03.Recap: CytoSorbents Q4 Earnings1
14.03.CytoSorbents Reports Fourth Quarter and Full Year 2023 Results373STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory...
► Artikel lesen
13.03.A Preview Of CytoSorbents' Earnings3
08.02.CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference10
17.01.Cytosorbents Corp - 8-K, Current Report10
17.01.CytoSorbents: Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb Intraoperatively in Heart Transplant Patients243PRINCETON, N.J., Jan. 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
► Artikel lesen
29.12.23What To Know About HC Wainwright & Co.'s Downgrade of CytoSorbents12
28.12.23Cytosorbents Corp - 8-K, Current Report6
28.12.23Dawson James sees Cytosorbents' Cytosorb as approvable, but raises risk13
28.12.23Cytosorbents, Cyclo Therapeutics among healthcare movers15
28.12.23US STOCKS Velo3D, Nova LifeStyle, CytoSorbents17
28.12.23Why Is Blood Purification Focused CytoSorbents Trading Lower Today?7
28.12.23CytoSorbents falls as blood purification device fails to meet study goal10
28.12.23CytoSorbents drops as blood purification system fails key trial11
28.12.23CytoSorbents: DrugSorb-ATR Study Fails To Meet Primary Effectiveness Endpoint6
28.12.23CytoSorbents Provides Update on the STAR-T Trial and Reports Final Independent Data and Safety Monitoring Board Recommendation573PRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
► Artikel lesen
13.12.23CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering18
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1